Clinical trials: Spliceosome Mutation
Myelodysplastic Syndrome
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome
In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine…
- Trial name
- NCT02060409
- Testing
- spliceosome
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Samsung Medical Center